Please login to the form below

Not currently logged in
Email:
Password:

ReNeuron makes shifts and additions to senior team

Including Sharon Grimster being named as general manager for Wales

edit-Sharon-GrimsterUK-based stem cell therapy company ReNeuron has announced a number of board and senior management changes.

Sharon Grimster has been named as general manager for Wales. Grimster has worked at the firm as interim chief development officer since last year and will now take on further responsibility for the development of ReNeuron's in-house manufacturing capability when it relocates its operations to South Wales later this year.

Grimster has extensive experience in advanced biologics development as has served in senior developments roles at businesses including F-star, Antisoma and Celltech.

Dr Randolph Corteling has been promoted to head of research from his current role of head of cell biology after joining in 2007. 

Olav Hellebø, CEO of ReNeuron, commented: “I am delighted to welcome Sharon Grimster and Randolph Corteling to the senior management team at ReNeuron.  Their skills and experience will be invaluable as ReNeuron continues its transition into a fully fledged clinical development business.”

Additionally, John Berriman, a non-executive director since 2011, has taken on the role of chairman after Bryan Morton stepped down.

Mark Docherty, a non-executive director since 2005, with step down from the role in September while John Sinden, chief scientific officer (CSO) and co-founder of ReNeuron and a board member since the beginning, will also step down from the board. Sinden will continue in his role as CSO.

Concerning the board alteration, Hellebø added: “I would also like to thank Bryan Morton and Mark Docherty for the immense contribution they have both made to the company's success over their respective long tenures on the board and to welcome John Berriman to the role of chairman.”

2nd April 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics